Abstract
In a previous paper [1] a simplified SEIR model applied to COVID-19 cases detected in Italy, including the lockdown period, has shown a good fitting to the time evolution of the disease during the observed period.
In this paper that model is applied to the initial data available for Italy in order to forecast, in a qualitative way, the time evolution of the disease spreading. The values obtained are to be considered indicative.
The same model has been applied both to the data relating to Italy and to some italian regions generally finding good qualitative results.
The only tuning parameter in the model is the ‘incubation period’ τ.
In this modelization the tuning parameter, together with the calculated growth rate of the exponential curve used to approximate the early stage data, are in strong relationship with the compartments’ transfer rates.
The relationships between the parameters simplify modeling by allowing a rough (not supported by statistical considerations) forecast of the time evolution, starting from the first period of growth of the diffusion.
Conclusions A simplified compartmental model that uses only the incubation period and the exponential growth rate as parameters is applied to the COVID-19 data for Italy in several periods of the initial growth of the diffusion showing the different stages of the spread evolution. The simplification is based on the strong protection measures that were in place in Italy during the lockdown period after the initial free diffusion.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Personal research, no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Personal research, no IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos